Pharmalyse Finance

Pharmalyse Finance

Created using Figma
DeFi Pharmaceutiical Ecosystem
Initial supply: 2,750 PALF

An initial supply of 2750 PALFIN tokens is to be minted by the deployer. The majority of the initial supply will be locked into Uniswap along with a proposed amount of 20 ETH contributed by the community during a pre-sale event to provide initial liquidity. The presale token price is 1 ETH = 50 PALF (capped at 1.0 ETH per investor).
To be announced
Token Details
Ticker
PALF
Total supply
2750
Accepted Currencies
ETH
Min Contribution
1
ETH
Company Details
Registered Company Name
Pharmalyser
Company Founded
May 12, 2020
Additional Details
Platform
ERC20 ETH
Categories
Platform

About Pharmalyse Finance

Pharmalyse Finance provides future-proof blockchain and AI (Artificial Intelligence) based provenance systems for the pharmaceutical and healthcare sector. Pharmalyse Finance digital solutions and services create efficiencies, accountability and transparency for supply chains, ease the burden of compliance requirements, reduce costs and eliminate counterfeit or substandard products.

Pharmalyse Finance Team

Verified 25%

Attention. There is a risk that unverified members are not actually members of the team

Laura W. James
Blockchain Strategist
verified
Asma Abed
CEO
unverified
Dragan Mclachlan
Business Development & Security Specialist
unverified
Liling Wang
CTO & Marketing Director
unverified

Pharmalyse Finance Interviews

Laura w. James
As a team member, сan you tell us about your role in the ICO project?
I have been working as Blockchain Strategist at Pharmalyse Finance, I am in charge of main strategy and vision of pharmalyse Finance.
What do you think about idea?
idea comes from a revolution in pharmaceutical industry on Defi ecosystem., Having decentralized finance platform in pharmaceutical market.

Pharmalyse Finance Last News

  • Due to potential time differences in information updates, please verify the accuracy of each ICO project through its official website or other official communication channels.
  • This information is not intended as a recommendation or suggestion for ICO investment. Please conduct thorough research on the relevant information and make your own informed decision regarding ICO participation.
  • If you identify any issues or errors in this content, or if you wish to submit your own ICO project for listing, please contact us via email at info@icoholder.com.
Please read the disclaimer and risk warning. Show disclaimer and risk warning.